NCT01476592View on ClinicalTrials.gov

A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

October 11, 2018

Conditions
Neuroendocrine Tumor
Interventions
DIETARY_SUPPLEMENT

Resveratrol

5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.

Trial Locations (1)

53792

University of Wisconsin, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT01476592 - A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors | Biotech Hunter | Biotech Hunter